Wei Pan

Wei Pan

Auto-generated profile, based on publicly available information

Wei Pan

Aier Academy of Ophthalmology, Central South University, Changsha, China

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 January 2025 in The Lancet Regional Health - Western Pacific
Verified
Journal Article
Open access
WPWei Pan
Wei Pan
SSSeang-Mei Saw
Seang-Mei Saw
TWTien Yin Wong
Tien Yin Wong
IMIan Morgan
Ian Morgan
ZYZhikuan Yang
Zhikuan Yang
WLWeizhong Lan
Weizhong Lan
Myopia rates have risen in the past decades in China. New strategies for the prevention and control of myopia are now available, and understanding the prevalence and future trends in myopia and high myopia in children and adolescents in China may provide insights into the impact of implementing these measures. The study aims to provide updated data on the prevalence of myopia and high myopia in children and to project temporal trends in prevalence from 2020 to 2050 in China. A systematic review and meta-analysis searching several databases in both English and Chinese: PubMed, Web of Science, Science Direct, China National Knowledge Infrastructure (CNKI), Wanfang, China Science and Technology Journal Database (CSTJ) with date limits from 01/01/2010 to 11/23/2024 was conducted. We included population-based or school-based studies in China that determined the myopia prevalence, based on the cycloplegic refraction, in children under 20. Studies with a response rate <70% or sample size <200 were excluded. A fixed-effect meta-analysis was used, and projections were made based on three scenarios: experience-based, maximum growth (maximum near-work, minimal outdoor time), and minimum growth (2 h outdoor time daily). From 6555 reports, 82 studies with 218,794 participants were included. The overall myopia prevalence was 36.6% (95% CI: 36.4%, 36.8%), with rates of 2.6% in ages 0-4, 22.0% in ages 5-9, 45.4% in ages 10-14, and 67.2% in ages 15-19. High myopia prevalence was 5.3% overall, with rates of 0.1% in ages 0-4, 1.1% in ages 5-9, 3.0% in ages 10-14, and 9.5% in ages 15-19. Projections for 2030 under minimum growth, experience-based, and maximum growth scenarios were 26.8%, 46.2%, 56.0%; 2040 were 19.6%, 54.4%, 65.6%; and 2050 were 14.4%, 61.3%, 71.9%, respectively. China is facing a substantial and potentially worsening epidemic of childhood myopia. This information will provide data for guiding implementation and evaluating the effectiveness of existing and new nationwide myopia prevention and control programs. The Science and Technology Innovation Program of Hunan Province, China (2023RC1079, 2024RC5002).

1 May 2018 in JAMA Ophthalmology
Verified
Journal Article
Open access
PDF file
LSLucia Sobrin
Lucia Sobrin
LSLynn K. Stanwyck
Lynn K. Stanwyck
WPWei Pan
Wei Pan
RHRebecca A. Hubbard
Rebecca A. Hubbard
JKJohn H. Kempen
John H. Kempen
BVBrian L. VanderBeek
Brian L. VanderBeek
Importance Understanding the role of vitamin D—which regulates inflammatory responses—in noninfectious uveitis (an inflammatory disease) may provide insight into treatment and prevention of this disease. Objective To investigate whether there is an association between hypovitaminosis D and incident noninfectious uveitis. Design, Setting, and Participants In a retrospective case-control study, data from a health care claims database containing deidentified medical claims from a large private insurer were used to identify 558 adults enrolled from January 1, 2000, to December 31, 2016, who received a diagnosis of noninfectious uveitis from an eye care clinician (with receipt of a confirmatory diagnosis within 120 days of the initial diagnosis) and who had a vitamin D level measured within 1 year before the first diagnosis. Exclusion criteria included having systemic disease or receiving medication known to lower vitamin D levels, having undergone intraocular surgery, and having infectious uveitis. Each case patient was matched with 5 controls on the basis of age, sex, race/ethnicity, and index date (2790 controls). The controls had vitamin D level determined either within 1 year before or within 6 months after receiving an eye examination with normal findings. Multiple logistic regression models were used to examine the association between hypovitaminosis D and noninfectious uveitis. Main Outcomes and Measures The primary, prespecified analysis assessed the association of noninfectious uveitis with hypovitaminosis D (vitamin D level ≤20 ng/mL). Results The 558 cases and 2790 controls were matched on age, and each group had a mean (SD) age of 58.9 (14.7) years. Among the cohort of 3348 patients, 2526 (75.4%) were female, and the racial/ethnic distribution in the matched samples was 2022 (60.4%) white, 552 (16.5%) black, 402 (12.0%) Hispanic, 162 (4.8%) Asian, and 210 (6.3%) unknown. Patients with normal vitamin D levels had 21% lower odds of having noninfectious uveitis than patients with low vitamin D levels (odds ratio [OR], 0.79; 95% CI, 0.62-0.99;P = .04). In a race-stratified analysis, an association between vitamin D and uveitis was found in black patients (OR, 0.49; 95% CI, 0.30-0.80;P = .004) and was qualitatively similar but nonsignificant in white patients (OR, 0.87; 95% CI, 0.62-1.21;P = .40) and Hispanic patients (OR, 0.60; 95% CI, 0.33-1.10;P = .10). Conclusions and Relevance This and other reports have found an association between hypovitaminosis D and noninfectious uveitis. However, these studies cannot establish a causal relationship. Prospective studies are warranted to evaluate whether hypovitaminosis D causes increased risk of uveitis and the role of vitamin D supplementation in prevention and treatment of uveitis.

Verified
Journal Article
Open access
PDF file
JQJinyan Qi
Jinyan Qi
WPWei Pan
Wei Pan
TPTing Peng
Ting Peng
Ling ZengLing Zeng
Ling Zeng
XLXiaoning Li
Xiaoning Li
Heping XuHeping Xu
Heping Xu
This retrospective study investigated circulating immune cell alteration in patients with myopic retinopathy. Blood test results and demographic and ocular information of 392 myopic patients and 129 emmetropia controls who attended Changsha Aier Eye Hospital from May 2017 to April 2022 were used in this study. Compared with emmetropia, the percentages of neutrophils and basophils and neutrophil/lymphocyte ratio were significantly higher in myopic patients, whereas the percentages of monocytes and lymphocytes and the counts of lymphocytes and eosinophils were significantly lower in myopic patients. After adjusting for age and hypertension/diabetes, the difference remained. Interestingly, the platelet counts were significantly lower in myopic patients after the adjustments. Further subgroup analysis using multivariable linear regression showed that higher levels of neutrophils, neutrophil/lymphocyte ratio, and platelet/lymphocyte ratio, lower levels of monocytes, eosinophils, lymphocytes, and platelets, were related to myopic peripheral retinal degeneration (mPRD) and posterior staphyloma (PS). A higher level of basophils was linked to myopic choroidal neovascularization (mCNV). Our results suggest that higher levels of circulating neutrophils and neutrophil/lymphocyte ratio, lower monocytes, eosinophils, lymphocytes, and platelets are related to mild myopic retinopathy. A higher level of circulating basophils is related to the severe form of myopic retinopathy, such as mCNV.

1 May 2019 in Retina
Verified
Journal Article
Open access
AKAnton M. Kolomeyer
Anton M. Kolomeyer
MMMaureen G. Maguire
Maureen G. Maguire
WPWei Pan
Wei Pan
BVBrian L. MD VanderBeek
Brian L. MD VanderBeek
Purpose: To determine whether oral beta-blockers (BBs) are associated with the development of neovascular age-related macular degeneration (nAMD). Methods: Retrospective cohort study of patients from 2000 to 2014 using data from a large national U.S. insurer's administrative medical claims database. Patients with nonexudative AMD who initiated (index date) BB, a calcium channel blocker (CCB), an angiotensin-converting enzyme/angiotensin receptor blocker, or a diuretic. Patients were excluded for <2 years in the plan before the index date, any history of nAMD or diagnosis, or treatment for an ocular disease that could be confused with nAMD. Hazard of developing of nAMD was the main outcome measure. Primary analysis compared BB with CCB patients with BB versus the other classes as secondary analyses. In addition, a sensitivity analysis was performed between BB and CCB cohorts using 1:1 propensity score matching. Cox proportional hazard regression was performed to estimate the hazard ratio (HR) of developing nAMD at 90, 180, and 365 days for BB. Covariates of interest included demographic information, year of index date, number of antihypertensive medications, and other comorbid systemic conditions. Results: Eighteen thousand seven hundred and fifty-four BB patients and 12,784 CCB patients met criteria for inclusion. After controlling for covariates, patients on BB had a lower hazard for nAMD at both 90 and 180 days than patients on CCB (HRs: 0.67–0.71; P < 0.01 for both) and diuretics (HRs: 0.55–0.62; P < 0.01). Patients on BB versus angiotensin-converting enzyme/angiotensin receptor blocker at all time points and BB versus CCB and diuretics at 365 days did not have a significantly lower association with nAMD (HR: 0.73–0.85; P > 0.06 for all comparisons). A sensitivity analysis using propensity score matching yielded similar results with patients on BB significantly less likely to develop nAMD at 90 and 180 days (HR: 0.70–0.76; P < 0.049 for both) but not at 365 days (HR: 0.88; P = 0.30) compared with patients on CCB. Conclusion: No evidence was found that BB usage increased the hazard for nAMD relative to other antihypertensive medications.

1 December 2024 in Journal of Inflammation Research
Verified
Journal Article
Open access
PDF file
LZLing Zeng
Ling Zeng
ZYZhikuan Yang
Zhikuan Yang
WPWei Pan
Wei Pan
DLDing Lin
Ding Lin
YTYao Tang
Yao Tang
XLXiaoning Li
Xiaoning Li
Purpose: In this study, we aimed to investigate the relationship between the intraocular levels of inflammatory factors and myopia-related retinal vascular and neuronal degeneration. Patients and Methods: One hundred and forty-seven patients with Implantable Collamer Lens (ICL) implantation were enrolled and all participants received comprehensive ophthalmic examination. About 100~150 ul of aqueous humor was collected immediately before ICL surgery. The levels of inflammatory factors including Aggrecan, April, BAFF, CCL5, CD163, Chi3l1, gp130, IL-6Rα, IL-8, IL-10, IL-11, IL-12, IL-19, IL-27, IL-28A, IL-34, IFN-β, IFN-γ, MMP-1, MMP-2, MMP-3 and PTX3 in the aqueous humor were measured using the Luminex Multiplexing system. Results: Results showed that aqueous humor levels of pro-inflammatory factors Chi3l1, IL-6Rα, IL-8, IL-12, IL-27, inflammation-related cytokines April, BAFF and IL-34 progressively increased from the progression of myopic retinopathy. Conversely, the aqueous levels of IL-11 and Aggrecan gradually decreased from the progression of myopic retinopathy. Correlation analysis showed that the intraocular levels of Chi3l1, IL-6Rα, IL-8, IL-27 and BAFF were negatively correlated with retinal vascular density. The intraocular level of IL-6Rα was negatively correlated with retinal neuronal thickness. Protein–Protein Interaction (PPI) analysis revealed that Chi3l1 and Aggrecan were the upstream cytokines that affect IL-10 and IL-8 in the pathological myopic eyes. KEGG pathway analysis showed that cytokine–cytokine receptor interaction, JAK-STAT signaling pathway, rheumatoid arthritis, and chagas disease were influenced by these altered inflammatory factors (adjusted p-value< 0.001). Conclusion: The production of inflammatory factors in the eyes of individuals with high myopia and pathological myopia was altered, and the elevated levels of intraocular pro-inflammatory factors such as Chi3l1, IL-6Rα, and IL-8 were closely associated with myopia-related retinal microvascular and neurodegeneration.

15 October 2025 in Ophthalmic and Physiological Optics
Verified
Journal Article
Closed access
GRGuangyao Ran
Guangyao Ran
XLXiaoning Li
Xiaoning Li
LWLongbo Wen
Longbo Wen
JHJie Huang
Jie Huang
SYShuo Yang
Shuo Yang
ZYZhikuan Yang
Zhikuan Yang